Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:8:120-5.
doi: 10.2174/1745017901208010120. Epub 2012 Nov 2.

Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups

Bernardo Dell'osso  1 , Giulia Camuri, Cristina Dobrea, Massimiliano Buoli, Marta Serati, A Carlo Altamura
Affiliations

Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups

Bernardo Dell'osso et al. Clin Pract Epidemiol Ment Health. 2012.

Abstract

Objective: Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is currently approved in many countries for the treatment of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The present naturalistic study was aimed to investigate tolerability of Duloxetine in a sample of patients with affective disorders and psychiatric/medical comorbidity, comparing tolerability in monotherapy versus polytherapy and across different age groups.

Methods: The sample included 165 patients, affected by anxiety and/or mood disorders with or without comorbidity, who had been taken Duloxetine for at least 1 month. Sample variables were collected through a retrospective chart review.

Results: Most common primary diagnoses were MDD (49.1 %), Bipolar Disorder (BD) (15.7 %) and GAD (5.5%). The 40 % of the sample had psychiatric comorbidity: in particular, anxiety disorders (15.8 %) (GAD 7.9%, Panic Disorder -PD- 7.3%) and personality disorders (9.1%) as the most frequent ones. With respect to medical comorbidities (68% of the sample), hypertension (12.1%) and diabetes (7.3%) were the most common ones. Mean duration of treatment and dosage of Duloxetine were, respectively, 11 months (± 9.1) and 70 mg/day (± 28.6). The 68 % of the sample received Duloxetine in association with other drugs. Minor side-effects, in particular drowsiness and gastrointestinal problems, were reported by 15 % of the sample. No difference in terms of tolerability across distinct groups, divided on the basis of mono- vs polytherapy as well as of different age, was found.

Conclusion: Duloxetine, mostly administered in patients with affective disorders with psychiatric/ medical comorbidity and in association with other drugs, appeared to be well tolerated, showing limited rates of side effects of mild intensity. Further naturalistic studies are warranted to confirm present results.

Keywords: Affective disorders; Duloxetine; medical comorbidity; psychiatric comorbidity; serotonin norepinephrine reuptake inhibitors; tolerability..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Polytherapy vs monotherapy in the total sample and accros different age groups.
Fig. (2)
Fig. (2)
Side effects distribution in the overall sample.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol. 2010;25:17–29. - PubMed
    1. Sussman N. SNRIs versus SSRIs: mechanisms of action in treating depression and painful physical symptoms. Prim Care Companion J Clin Psychiatry. 2003;5:19–26. - PubMed
    1. Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23–31. - PMC - PubMed
    1. Carter NJ, McCormack PL. Duloxetine. A review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23:523–0. - PubMed
    1. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:1142–50. - PubMed

LinkOut - more resources